Login

Lost your Password?

EMBARC

The European Bronchiectasis Registry

Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.

Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A. / Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017. Print 2018 Jan. No abstract

The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis.

Metersky ML, Aksamit TR, Barker A, et al / Ann Am Thorac Soc. 2018 Mar;15(3):365-370. doi: 10.1513/AnnalsATS.201706-426OC.

Characterisation of the "Frequent Exacerbator Phenotype" in Bronchiectasis.

Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ. / Am J Respir Crit Care Med. 2018 Jan 22. doi: 10.1164/rccm.201711-2202OC. [Epub ahead of print]

Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report.

Hill AT, Barker AF, Bolser DC, Davenport P, Ireland B, Chang AB, Mazzone SB, McGarvey L. / Chest. 2018 Jan 31. pii: S0012-3692(18)30091-6. doi: 10.1016/j.chest.2018.01.014. [Epub ahead of print]

Upper airway involvement in bronchiectasis is marked by early onset and allergic features.

Shteinberg M, Nassrallah N, Jrbashyan J, Uri N, Stein N, Adir Y. / ERJ Open Res. 2018 Jan 19;4(1). pii: 00115-2017. doi: 10.1183/23120541.00115-2017. eCollection 2018 Jan.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. / Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. / Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

RESPIRE: breathing new life into bronchiectasis.

Chotirmall SH, Chalmers JD. / Eur Respir J. 2018 Jan 25;51(1). pii: 1702444. doi: 10.1183/13993003.02444-2017. Print 2018 Jan. No abstract available.

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD. / Eur Respir J. 2018 Jan 31;51(2). pii: 1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb.

Pseudomonas aeruginosa infection and exacerbations in bronchiectasis: more questions than answers.

Martinez-García MA. / Eur Respir J. 2018 Jan 31;51(2). pii: 1702497. doi: 10.1183/13993003.02497-2017. Print 2018 Feb. No abstract available